AKB 4924

Drug Profile

AKB 4924

Alternative Names: AKB-4924; GB-004

Latest Information Update: 03 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Procter & Gamble
  • Developer Aerpio Pharmaceuticals
  • Class Anti-inflammatories; Piperazines; Pyridones; Small molecules
  • Mechanism of Action Hypoxia inducible factor 1 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Inflammatory bowel diseases

Most Recent Events

  • 25 Jun 2018 AKB 4924 licensed to Gossamer Bio worldwide
  • 25 Jun 2018 Aerpio Therapeutics initiates enrolment in a phase I trial in Healthy volunteers
  • 15 May 2018 Aerpio plans to initiate a multiple ascending dose study for Ulcerative colitis in the second quarter of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top